左西替利嗪联合孟鲁司特治疗儿童慢性特发性荨麻疹的疗效观察

廖骏华; 杨华英; 张良

doi:10.13898/j.cnki.issn.1000-2200.2017.09.021

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

左西替利嗪联合孟鲁司特治疗儿童慢性特发性荨麻疹的疗效观察

廖骏华 , 杨华英 , 张良

文章导航 > 蚌埠医学院学报 > 2017, 42 > 9: (1223-1226)

引用本文:

Citation:

左西替利嗪联合孟鲁司特治疗儿童慢性特发性荨麻疹的疗效观察

四川省自贡市妇幼保健院儿科, 643000

作者简介: 廖骏华(1982-),男,主治医师.

中图分类号: R758.24

Effect of levocetirizine combined with montelukast in the treatment of chronic idiopathic urticarial in children

Department of Pediatrics, Zigong Maternal and Child Health Hospital, Zigong Sichuan 643000, China
CLC number: R758.24

摘要: 目的：观察盐酸左西替利嗪联合孟鲁司特治疗儿童慢性特发性荨麻疹（CIU）的疗效及安全性。方法：选取94例CIU患儿，随机分成观察组和对照组（各47例）。2组均采用口服盐酸左西替利嗪口服液，其中观察组同时加用孟鲁司特钠咀嚼片，疗程为28 d，分别在治疗后第14天与第28天时采用症状体征积分观察疗效，同时记录不良反应事件，在停药后6周及12周后进行随访。结果：观察组患儿在治疗第14天及第28天时，总有效率分别为74.5%及87.2%，均高于对照组的55.3%和70.2%（P<0.05）。经治疗后第14天与第28天，2组患儿的主要临床症状体征评分均明显低于治疗前（P<0.01），治疗后第14天及第28天观察组风团持续发作时间及发作频率评分均显著少于对照组（P<0.01），观察患儿停药后第6周及第12周复发率分别为12.8%及17.0%，均低于对照组的29.8%和36.2%（P<0.05）。对照组和观察组的不良反应发生率分别为10.6%及8.51%，差异无统计学意义（P>0.05）。结论：西替利嗪联合应用孟鲁司特治疗儿童慢性特发性荨麻疹安全、有效，其疗效及复发率均优于单用左西替利嗪，值得在临床上推广运用。
- 慢性特发性荨麻疹 /
- 左西替利嗪 /
- 孟鲁司特 /
- 儿童
Abstract: Objective: To evaluate the efficacy and safety of levocetirizine combined with montelukast in the treatment of chronic idiopathic urticaria(CIU) in children.Methods: Ninety-four children with CIU were randomly divided into the observation group(47 cases) and control group(47 cases).Two groups were treated with levocetirizine by oral for 28 days.The observation group were additionally treated with montelukast for 28 days.The efficacy in two groups were observed after 14 and 28 days of treatment using the scores of symptoms and signs,and the adverse events were recorded.All cases were followed up after 6 weeks and 12 weeks of stopping treatment.Results: The effective rates in observation group on 14th day and 28th day(74.5% and 87.2%) were higher than those in control group(55.3% and 70.2%),respectively(P<0.05).After treatment,the scores of symptoms and signs in two groups were obviously lower than those before treatment(P<0.01),and the wheal occurrence and duration in observation group were significantly less than those in control group on 14th day and 28th day(P<0.01).The recurrence rates in observation group after 6 weeks and 12 weeks of stopping treatment(12.8% and 17.0%) were lower than those in control group(29.8% and 36.2%),respectively(P<0.05).The incidence rates of adverse reaction in control group and observation group were 10.6% and 8.51%,respectively,and the difference of which between two groups was not statistically significant(P>0.05).Conclusions: Compared with levocetirizine,the treatment of CIU with levocetirizine combined with montelukast is safe,effective and less recurrence rate,which is worthy of popularization and application.
- chronic idiopathic urticaria /
- levocetirizine /
- montelukast /
- child

[1]	黄兰雅.慢性荨麻疹治疗研究进展[J].中外妇儿健康,2011,19(6):100.
[2]	SANTOS JC,DE BRITO CA,FUTATA EA.Up-regulation of chemokine C-C ligand 2(CCL2) and C-X-C chemokine 8(CXCL8) expression by monocytes in chronic idiopathic urticarial[J].Clin Exp Immunol,2012,167(1):129.
[3]	GUPTA SP,JINDAL N,GUPTA S,et al.Clinico-etiological study with response to specific treatment in childhood urticaria[J].Indian Dermatol Online J,2011,2(2):64.
[4]	ZUBERBIER T,ASERO R,BINDSLEV-JENSEN C,et al.EAACI/GA2LEN/EDF/WAO guideline:management of urticarial[J].Allergy,2009,64(10):1427.
[5]	吴念雪,罗晓燕,卢宏昌,等.盐酸左西替利嗪治疗儿童慢性荨麻疹多中心随机对照研究[J].儿科药学杂志,2014,20(11):9.
[6]	李学燕,于海凤.消风散联合地氯雷他定治疗小儿慢性特发性尊麻疹的疗效观察[J].中国医药科学,2014,4(6):127.
[7]	中华医学会皮肤性病学分会免疫学组.中国荨麻疹治疗指南(2014版)[J].中华皮肤科杂志,2014,47(7):514.
[8]	KALPAKLIOGLU F,BACCIOGLU A.Efficacy and safety of H1-antihistamines:an update[J].Antiinflamm Antiallergy Agents Med Chem,2012,11(3):230.
[9]	AUGUSTIN M,EHRLE S.Safety and efficacy of desloratadine in chronic idiopathic urticaia in clinical practice:an observational study of 9246 patients[J].J Eur Acad Dermatol Venereol,2009,23(3):292.
[10]	刘笑咏.孟鲁司特治疗儿童荨麻疹的临床疗效研究[J].中国医疗美容,2014,6:85.
[11]	WOSZCZEK G,CHEN LY,ALSAATY S,et al.Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists[J].J Immunol,2010,184(4):2219.
[12]	钟慧,洪建国.半胱氨酰白三烯受体拮抗剂孟鲁司特的研究进展[J/CD].中华哮喘杂志(电子版),2011,5(5):362.
[13]	袁永贵,凌丽芬.孟鲁司特联合依匹斯汀治疗慢性荨麻疹疗效观察[J].皮肤病与性病,2014,36(1):29.

[1]	陈娟 . 孟鲁司特治疗儿童咳嗽变异性哮喘的临床疗效观察. 蚌埠医学院学报, 2015, 40(5): 622-623,626. doi: 10.13898/j.cnki.issn.1000-2200.2015.05.020
[2]	冷建刚 , 杨泽民 , 桑旭 , 王磊 , 赵武 . 吸入用布地奈德联合孟鲁司特钠、左西替利嗪治疗6~12岁小儿咳嗽变异性哮喘的临床疗效观察. 蚌埠医学院学报, 2023, 48(4): 453-456. doi: 10.13898/j.cnki.issn.1000-2200.2023.04.008
[3]	余文凯 . 孟鲁司特联合沙美特罗替卡松治疗咳嗽变异性哮喘疗效观察. 蚌埠医学院学报, 2015, 40(2): 197-199. doi: 10.13898/j.cnki.issn.1000-2200.2015.02.018
[4]	高大明 , 马家明 . 孟鲁司特治疗毛细支气管炎25例疗效观察. 蚌埠医学院学报, 2010, 35(1): 46-47.
[5]	孙秀玲 . 孟鲁司特治疗小儿毛细支气管炎的临床效果研究. 蚌埠医学院学报, 2016, 41(7): 936-937. doi: 10.13898/j.cnki.issn.1000-2200.2016.07.034
[6]	张文娟 , 孙勇 . 丙酸氟替卡松联合盐酸班布特罗治疗儿童哮喘疗效观察. 蚌埠医学院学报, 2005, 30(4): 315-316.
[7]	汪珊 , 韦红 . 儿童原发性肾病综合征40例临床分析. 蚌埠医学院学报, 2014, 38(3): 345-347.
[8]	谢怀珍 , 董传莉 . 儿童慢性咳嗽60例病因探讨. 蚌埠医学院学报, 2007, 32(6): 703-704.
[9]	杨武 . 儿童慢性咳嗽60例病因分析. 蚌埠医学院学报, 2011, 36(11): 1229-1230.
[10]	马勇 , 朱明英 . 儿童特发性血小板减少性紫癜84例诊治体会. 蚌埠医学院学报, 2010, 35(1): 62-63.
[11]	程学文 . 儿童自发性脑出血误诊13例分析. 蚌埠医学院学报, 2014, 38(6): 776-777.
[12]	陈信 , 彭万胜 , 瞿色华 , 张阵 , 武玉猛 , 赵武 . 5岁及以下儿童非特异性慢性咳嗽的病因分析. 蚌埠医学院学报, 2016, 41(3): 302-304,307. doi: 10.13898/j.cnki.issn.1000-2200.2016.03.007
[13]	薛丽芬 . 无锡市蠡湖社区7岁以下儿童5年体格检查结果分析. 蚌埠医学院学报, 2010, 35(12): 1300-1301.
[14]	陈贞祥 , 沈怀云 , 诸宏伟 , 董淮富 . 雾化吸入布地奈德、硫酸特布他林佐治小儿重症肺炎30例. 蚌埠医学院学报, 2011, 36(5): 467-469.
[15]	朱磊 , 刘冉 , 胡丹 , 朱晓新 , 刘开勋 , 魏海燕 . 艾司洛尔对小儿重症手足口病心肌酶的影响. 蚌埠医学院学报, 2013, 37(12): 1570-1572.
[16]	刘小群 , 陈啸洪 , 张佩红 , 李华浚 . 慢性持续期哮喘患儿血清IL-17、TGF-β1水平变化及临床意义. 蚌埠医学院学报, 2016, 41(9): 1178-1180. doi: 10.13898/j.cnki.issn.1000-2200.2016.09.019
[17]	林宏华 . 儿童1型糖尿病32例临床分析. 蚌埠医学院学报, 2006, 31(5): 493-494.
[18]	魏广友 . 儿童急性中毒相关因素分析与干预策略. 蚌埠医学院学报, 2009, 34(10): 893-895.
[19]	刘安利 . 儿童支原体肺炎111例临床分析. 蚌埠医学院学报, 2013, 37(9): 1172-1174.
[20]	谢红 . 氟保护漆预防儿童龋齿的效果观察. 蚌埠医学院学报, 2016, 41(3): 340-342. doi: 10.13898/j.cnki.issn.1000-2200.2016.03.019

点击查看大图

计量

文章访问数: 5930
HTML全文浏览量: 829
PDF下载量: 80
被引次数: 0

左西替利嗪联合孟鲁司特治疗儿童慢性特发性荨麻疹的疗效观察

作者简介: 廖骏华(1982-),男,主治医师.

四川省自贡市妇幼保健院儿科, 643000

收稿日期: 2015-11-02

关键词:

摘要: 目的：观察盐酸左西替利嗪联合孟鲁司特治疗儿童慢性特发性荨麻疹（CIU）的疗效及安全性。方法：选取94例CIU患儿，随机分成观察组和对照组（各47例）。2组均采用口服盐酸左西替利嗪口服液，其中观察组同时加用孟鲁司特钠咀嚼片，疗程为28 d，分别在治疗后第14天与第28天时采用症状体征积分观察疗效，同时记录不良反应事件，在停药后6周及12周后进行随访。结果：观察组患儿在治疗第14天及第28天时，总有效率分别为74.5%及87.2%，均高于对照组的55.3%和70.2%（P<0.05）。经治疗后第14天与第28天，2组患儿的主要临床症状体征评分均明显低于治疗前（P<0.01），治疗后第14天及第28天观察组风团持续发作时间及发作频率评分均显著少于对照组（P<0.01），观察患儿停药后第6周及第12周复发率分别为12.8%及17.0%，均低于对照组的29.8%和36.2%（P<0.05）。对照组和观察组的不良反应发生率分别为10.6%及8.51%，差异无统计学意义（P>0.05）。结论：西替利嗪联合应用孟鲁司特治疗儿童慢性特发性荨麻疹安全、有效，其疗效及复发率均优于单用左西替利嗪，值得在临床上推广运用。

English Abstract

Effect of levocetirizine combined with montelukast in the treatment of chronic idiopathic urticarial in children

Department of Pediatrics, Zigong Maternal and Child Health Hospital, Zigong Sichuan 643000, China

Received Date: 2015-11-02

Abstract: Objective: To evaluate the efficacy and safety of levocetirizine combined with montelukast in the treatment of chronic idiopathic urticaria(CIU) in children.Methods: Ninety-four children with CIU were randomly divided into the observation group(47 cases) and control group(47 cases).Two groups were treated with levocetirizine by oral for 28 days.The observation group were additionally treated with montelukast for 28 days.The efficacy in two groups were observed after 14 and 28 days of treatment using the scores of symptoms and signs,and the adverse events were recorded.All cases were followed up after 6 weeks and 12 weeks of stopping treatment.Results: The effective rates in observation group on 14th day and 28th day(74.5% and 87.2%) were higher than those in control group(55.3% and 70.2%),respectively(P<0.05).After treatment,the scores of symptoms and signs in two groups were obviously lower than those before treatment(P<0.01),and the wheal occurrence and duration in observation group were significantly less than those in control group on 14th day and 28th day(P<0.01).The recurrence rates in observation group after 6 weeks and 12 weeks of stopping treatment(12.8% and 17.0%) were lower than those in control group(29.8% and 36.2%),respectively(P<0.05).The incidence rates of adverse reaction in control group and observation group were 10.6% and 8.51%,respectively,and the difference of which between two groups was not statistically significant(P>0.05).Conclusions: Compared with levocetirizine,the treatment of CIU with levocetirizine combined with montelukast is safe,effective and less recurrence rate,which is worthy of popularization and application.